22 employees
Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
2017
$23M
from 6 investors over 6 rounds
Sibylla Biotech raised $23M on October 4, 2022
Investors: 3B Future Health Fund, VI Partners AG, V-Bio Ventures, Indaco Venture Partners, Seroba-Kernel Ltd (Ireland) and Claris Ventures SGR SpA